Introduction: Prior in vivo murine studies suggest circadian oscillations for hematopoietic stem cell release, which are maintained following administration of granulocyte colony-stimulating factor (G-CSF) or plerixafor. Furthermore, retrospective data analysis of healthy donors who underwent G-CSF-induced mobilization demonstrated significantly increased CD34 + cell yields when collected in the afternoon compared with the morning.
Introduction
Hematopoietic progenitor cell (HPC) mobilization using granulocyte colony-stimulating factor (G-CSF) is currently the most frequent method to obtain HPC for allogeneic transplantation. The optimal dose and schedule remains uncertain [1] , but the National Marrow Donor Program uses a schedule of 10 μg/kg for 5 days, with the fifth dose~1 hour prior to the initiation of the first leukapheresis [2] . CD34 + cell doses >4.5 to 5×10 6 /kg are associated with improved overall survival and reduced transplant-related mortality in the allogeneic setting [3, 4] . Although obtaining this goal in a single apheresis is preferable for donor convenience and safety, only 68% of G-CSF mobilized allogeneic donors reach a CD34 + cell dose ≥4×10 6 /kg in a single apheresis, with a similar percentage for pegfilgrastim [5, 6] , and about 70% of allogeneic donors actually undergo two leukaphereses [2] . In addition, the timing of leukapheresis collection on days 5 and 6 is standardized based on staffing convenience rather than on kinetic data regarding the CD34 + cell number. Based on preclinical and clinical data showing circadian oscillations of hematopoietic progenitor and stem cell release that are maintained with G-CSF or plerixafor mobilization [7] [8] [9] [10] , we conducted a single-center, prospective cohort study in allogeneic donors undergoing standard National Marrow Donor Program G-CSF mobilization (10 μg/kg/day for 5 days, administered between 06:00 and 07:00 hours), with the hypothesis that evening CD34 + concentrations are significantly higher than morning CD34 + concentrations. This study is important because hematopoietic progenitor collections typically occur in the morning due to convenience. The National Marrow Donor Program regimen was chosen because it is the most frequently used G-CSF regimen for unrelated allogeneic donors in the United States.
Methods
This trial was a single-center, prospective cohort IRBapproved (Mount Sinai School of Medicine IRB, #08-0446) study in allogeneic sibling donors. Written and signed consent was obtained from both donors and recipients. All sibling donors for allogeneic transplants at Mount Sinai Medical Center from January 2009 to December 2011 were approached to participate. Baseline CD34 + concentrations prior to starting G-CSF were assessed with two separately collected samples. Donors were admitted the evening of day 3 of G-CSF to the Clinical Research Center at Mount Sinai and stayed through two nights until the morning of day 5 of G-CSF mobilization, when they were discharged to the apheresis center to start leukapheresis. All donors reported normal sleep habits on specific review of symptoms and, except for one from Wisconsin, lived in the New York City area and had no history of travel within the past month outside their normal time zone. (Figure 1 ). Blood was drawn through a 20-gauge angiocath attached to a medlock placed upon admission, to avoid distress from multiple needlesticks. Samples were drawn after discard of 2 ml PB, and were run using a standard technique (Stem-Kit 
Results
Eleven healthy allogeneic sibling donors were recruited into this study ( Table 1 ). All participants were over 45 years of age except for three donors (ages 20, 29, and 30) and were 10/10 HLA matched except for one donor, who was an 8/10 HLA match (mismatched at DRB1 and DQB1). Stem cell mobilization was successfully completed in all subjects, with all measurements completed except for one donor, in whom the 18:00 hours blood sample was drawn but misplaced. All recipients had a Karnofsky score of 90 or 100, received graft-versus-hostdisease prophylaxis with tacrolimus/methotrexate or cyclosporine/mycophenolate mofetil, and have either died or been followed for at least 1 year (Table 2) .
Average Figure 3A ) and the utility of using PB CD34 +
CD38
-compared with CD34 + alone to determine the optimal time for collection is worth exploring given the correlation between CD34 + CD38 -graft content and early engraftment in the allogeneic setting [11, 12] and long-term neutrophil and platelet reconstitution in the autologous transplant setting [13, 14] . 
Post-hoc
Kaplan-Meier analysis (although hypothesisforming only) showed a significant correlation (P = 0.02
Discussion
In previous human studies, there was an average >2-fold difference in baseline (nonmobilized) circadian variation in HPCs [7, 9, 10] . In this prospective cohort study of 11 G-CSF mobilized allogeneic sibling donors, there was a ], paired t tests) between day 4 and day 5 is consistent with a previous report [19] .
On the contrary, with a G-CSF effect alone one might expect the day 5 06:00 hours [CD34 + ] / [CD34 + CD38 -] to be significantly higher than the day 4 evening values; thus the absence of this finding is consistent with a circadian rhythm. Ethical considerations precluded postponing leukapheresis to evaluate the day 5 to day 6 PB HPC concentrations, which might effectively address the conundrum of dissecting the circadian rhythm from the G-CSF pharmacodynamic effect, which plateaus during this time period [19] .
The timing of G-CSF administration in the morning may have overridden endogenous evening peak HPC counts except in the youngest donors. In a study of serial administration of a 4-day G-CSF course at different hours of the day [20] , the peak of the CD34 + count on the fifth day occurred within several hours of the G-CSF administration time on the previous 4 days (Georg Bjarnason, personal communication). On day 5 of daily morning G-CSF administration, there was also a nonsignificant trend in 10 healthy volunteers towards a peak CD34 + count 2 hours after the G-CSF dose [19] . In the mouse model, where circadian rhythms were maintained with G-CSF mobilization [9] , human G-CSF was injected subcutaneously at 125 μg/kg every 12 hours for 4 days, and blood collection was always timed at 3 hours after the last dose of G-CSF. Perhaps the steadier serum levels of G-CSF obtained with every 12-hour dosing [21] is important for maintenance of the circadian rhythm, given G-CSF pharmacokinetics of a maximum serum concentration after subcutaneous administration for 2 to 8 hours and a half-life of~3.5 hours.
The circadian pattern of stem cell egress may be altered in older people, as it is notable that the three youngest donors had the highest [CD34 + ] mobilization, and reached or maintained their peak [CD34 + CD38 -] at day 4 midnight. Older patients do not mobilize hematopoietic progenitors as well as young subjects [22] and previous studies finding an endogenous circadian rhythm used as their subjects young mice aged 7 to 8 weeks old [9] or healthy volunteers with mostly an age range in their 20s and 30s [7] [8] [9] [10] .
Donor ailments or medications may have affected their circadian rhythm, as stem cell mobilization may be affected by diabetes [23] or by drugs affecting sympathetic tone [24, 25] . The two diabetic patients had relatively low CD34 + mobilization, while the asthmatic donor on the β 2 -adrenergic agonist albuterol (and α-adrenergic agonist pseudoephedrine) had the highest mobilization.
Finally, the circadian peak may have occurred between 18:00 and 00:00 hours and was thus missed. Previously reported~2-fold differences in PB [CD34 + ] / [CD34 + CD38 -] were seen at 20:00 hours compared with 08:00 hours collection times [9] . Previous mouse data suggest that the circadian HPC concentrations can fluctuate significantly over 4-hour intervals [8] .
The 
Conclusion
This is the first prospective cohort study based on preclinical mouse as well as retrospective clinical data to examine whether circadian oscillations to hematopoietic stem cell release are maintained with G-CSF (or plerixafor) mobilization. Such data are important because a simple change of collection time to coincide with the peak of circadian egress might theoretically optimize the number of HPC collected. Our data suggest that endogenous progenitor rhythms may be altered by pharmacodynamic effect and the timing of G-CSF, and also donor age, medical history, and medications. These findings have important implications for future study design using G-CSF or possibly other mobilizing agents to study HPC biology.
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